IL6-Mab

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Uveitic Macular Edema

Phase 3

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE MASKED, SHAM-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH UVEITIC MACULAR EDEMA

CompletedCTIS2022-501793-19-00

F. Hoffmann-La Roche AGUveitic Macular Edema

Start: 2023-04-21End: 2025-07-08Target: 46Updated: 2025-05-22

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE MASKED, SHAM-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH UVEITIC MACULAR EDEMA

CompletedCTIS2022-501794-39-00

F. Hoffmann-La Roche AGUveitic Macular Edema

Start: 2023-06-28End: 2025-11-27Target: 70Updated: 2025-10-16